The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Second Primary Tumors in Neurofibromatosis 1 Patients Treated for Optic Glioma: Substantial Risks After Radiotherapy
Abstract
Purpose: Optic pathway gliomas (OPGs) are the most common CNS tumor in neurofibromatosis 1 (NF1) patients. We evaluated the long-term risk of second tumors in NF1-related OPGs after radiotherapy. Patients and Methods: We reviewed 80 NF1 OPG patients from two NF1 clinics to evaluate the long-term risk of developing subsequent nervous system tumors, with or without radiotherapy. Results: Fifty-eight patients were assessable for second tumors. Nine (50%) of 18 patients who received radiotherapy after their OPGs developed 12 second tumors in 308 person-years of follow-up after radiotherapy. Eight (20%) of 40 patients who were not treated with radiotherapy developed nine tumors in 721 person-years of follow-up after diagnosis of their OPGs. The relative risk of second nervous system tumor after radiotherapy was 3.04 (95% CI, 1.29 to 7.15). Conclusion: There is a significantly increased risk of second nervous system tumors in those NF1 patients who received radiotherapy for their OPGs, especially when treated in childhood. Thus radiotherapy should only be used if absolutely essential in children with NF1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, A. S., Brummel‐Smith, K., Burgess, L., D'Agostino, R. B., Goldschmidt, J. W., Halter, J. B., Hazzard, W. R., Jahnigen, D. W., Phelps, C., Raskind, M., et al. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb02362.x · Cited by 1,331
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.5.311 · Cited by 1,282
Self-citationTumors of the Brain and Nervous System after Radiotherapy in Childhood
Ron, E., Modan, B., Boice, J. D., Alfandary, E., Stovall, M., Chetrit, A., & Katz, L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810203191601 · Cited by 934
Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1,728 patients
Friedman, J. M., & Birch, P. H. (1997) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19970516)70:2<138::aid-ajmg7>3.0.co;2-u · Cited by 432
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413
CANCER RISKS FROM MEDICAL RADIATION
Ron, E. (2003) · Health Physics · doi:10.1097/00004032-200307000-00011 · Cited by 382
Evans, D. G. R., Birch, J. M., Ramsden, R. T., Sharif, S., & Baser, M. E. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036319 · Cited by 301
Self-citationGuillamo, J.-S., Creange, A., Kalifa, C., Grill, J., Rodriguez, D., Doz, F., Barbarot, S., Zerah, M., Sanson, M., Bastuji-Garin, S., et al. (2003) · Brain · doi:10.1093/brain/awg016 · Cited by 295
Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients
Ars, E., Kruyer, H., Morell, M., Pros, E., Serra, E., Ravella, A., Estivill, X., & Lázaro, C. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.6.e82 · Cited by 183
Salvati, M., Frati, A., Russo, N., et al. (2003) · Surgical Neurology · doi:10.1016/s0090-3019(03)00137-x · Cited by 156
de Vathaire, F., Hawkins, M. M., Campbell, S., Oberlin, O., Raquin, M. A., Schlienger, J.-Y., Shamsaldin, A., Diallo, I., Bell, J., Grimaud, E., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690300 · Cited by 150
Neurofibromatosis type 1 and sporadic optic gliomas
Singhal, S. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.1.65 · Cited by 141
Knauf, J. A., Ouyang, B., Knudsen, E. S., Fukasawa, K., Babcock, G. F., & Fagin, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511690200 · Cited by 93
Therapy-induced malignant neoplasms in Nf1 mutant mice
Chao, R. C., Pyzel, U., Fridlyand, J., Kuo, Y., Teel, L., Haaga, J., Borowsky, A. D., Horvai, A., Kogan, S. C., Bonifas, J. M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.011 · Cited by 48
Cited by
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045906 · Cited by 1,053
Self-citationGutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.4 · Cited by 862
Self-citationNeurofibromatosis type 1: a multidisciplinary approach to care
Hirbe, A. C., & Gutmann, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70063-8 · Cited by 626
Optic pathway gliomas in neurofibromatosis‐1: Controversies and recommendations
Listernick, R., Ferner, R. E., Liu, G. T., & Gutmann, D. H. (2007) · Annals of Neurology · doi:10.1002/ana.21107 · Cited by 576
Self-citationNeurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective
Ferner, R. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70075-3 · Cited by 511
Self-citation
Metadata
- Authors
- Sharif, S., Ferner, R., Birch, J. M., Gillespie, J. E., Gattamaneni, H. R., Baser, M. E., & Evans, D. G. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-06-01
- Volume
- 24
- Issue
- 16
- Pages
- 2570-2575
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2167453812
- Cited by
- 377
- References
- 14
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.